Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates.
Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium.
For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register.
For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.

Patent details

97C0106 Product name: TACROLIMUS.

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic information

Application number:
97C0106
Type:
Certificate
SPC type:
Medical
Basic patent number:
851152025
Status:
Publication number:
97C0106
1rst applicant's nationality:
Procedural language:
French

Paediatric extension

SPC Extension filing date:
SPC Extension status:
SPC Extension grant date:
SPC Extension Rejection Date:

Marketing authorization

1

Marketing authorization number:
3511 IE 1 F 4
Marketing authorization type:
National/EU
Designates country:
No
Marketing authorization date:
28/04/1997
Marketing authorization status:
Accepted
Marketing authorization country:
Belgium (BE)

2

Marketing authorization number:
13424/0001
Marketing authorization type:
EEA
Designates country:
Yes
Marketing authorization date:
07/06/1994
Marketing authorization status:
Accepted
Marketing authorization country:
United Kingdom (GB)

Dates

Filing date:
21/10/1997
First marketing authorization date:
07/06/1994
Grant date:
02/06/1998
Activation date:
30/11/2005
BE Publication date:
Lapsed date:
Expiration date (if granted and all annual fees paid):
Basic SPC Expiration (if granted and all annual fees paid):
SPC/SPC Extension Expiration (if granted and all annual fees paid):
Rejection date:
Withdrawal date:

Applicant

Name:
Astellas Pharma Inc.
Legal Form:
From:
11/01/2006
Address:
3-11 Nihonbashi-Hondo 2-chome, Chuo-ku, Tokyo 103-8411(JP), JP
To:

Publication

Bulletin

Bulletin heading:
Journal edition number:
Publication date:
02/06/1998
Description:

Annual fee

Annual fee(s) Due Date:
Annual fee number:
Expected payer:
Last annual fee payment date:
30/10/2008
Last annual fee paid number:
Payer:

Additional information section

Status:
EX EXTINCTION
Case kind / Max duration / Publication code:
Certificat Complémentaire de Protection pour les Médicaments
Basic patent details (Patent law 1854):
Representative details:
MODRIE Guy-S.A. NOVAGRAAF N.V.-Chaussée de la Hulpe 187 - B 1170 BRUXELLES
Inventor(s) details:
History of owners:
(1) 21.10.1997 : FUJISAWA PHARMACEUTICAL CO. LTD * (JP) 4-7, Doshomachi 3-chome, Chuo-ku Osaka-shi Osaka 541 * (2) 11.01.2006 : YAMANOUCHI PHARMACEUTICAL CO. LTD * (JP) 3-11, Nihonbashi-Hondo 2-chome, Chuo-ku, Tokyo *
Filing date Document type Publication Type Document Description Number of pages File Type
Certificate PDF /6/0/1/0/7/0300970106/migrated-docs/97C0106_0_97C0106.pdf